key: cord-0786199-hzs514sp authors: Gulati, Anil; Jain, Dinesh; Agrawal, Nilesh Radheshyam; Rahate, Prashant; Choudhuri, Rajat; Das, Soumen; Dhibar, Deba Prasad; Prabhu, Madhav; Haveri, Sameer; Agarwal, Rohit; Lavhale, Manish S. title: Resuscitative Effect of Centhaquine (Lyfaquin(®)) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial date: 2021-05-10 journal: Adv Ther DOI: 10.1007/s12325-021-01760-4 sha: 94b32778ade0dec6f1a593c6e6239c318a8a3d4d doc_id: 786199 cord_uid: hzs514sp INTRODUCTION: Centhaquine (Lyfaquin(®)) showed significant efficacy as a resuscitative agent in animal models of haemorrhagic shock. Its safety and tolerability were confirmed in healthy human volunteers. In this study, our primary objective was to determine the safety, and the secondary objective was to assess the efficacy of centhaquine in patients with hypovolemic shock. METHODS: A prospective, multicentre, randomized phase II study was conducted in male and female patients aged 18–70 years with hypovolemic shock having systolic BP ≤ 90 mmHg. Patients were randomized in a 1:1 ratio to either the control or centhaquine group. The control group received 100 ml of normal saline infusion over 1 h, while the centhaquine group received 0.01 mg/kg of centhaquine in 100 ml normal saline infusion over 1 h. Every patient received standard of care (SOC) and was followed for 28 days. RESULTS: Fifty patients were included, and 45 completed the trial: 22 in the control group and 23 in the centhaquine group. The demographics of patients in both groups were comparable. No adverse event related to centhaquine was recorded in the 28-day observation period. The baseline, Injury Scoring System score, haemoglobin, and haematocrit were similar in both groups. However, 91% of the patients in the centhaquine group needed major surgery, whereas only 68% in the control group (p = 0.0526). Twenty-eight-day all-cause mortality was 0/23 in the centhaquine group and 2/22 in the control group. The percent time in ICU and ventilator support was less in the centhaquine group than in the control group. The total amount of vasopressors needed in the first 48 h of resuscitation was lower in the centhaquine group than in the control group (3.12 ± 2.18 vs. 9.39 ± 4.28 mg). An increase in systolic and diastolic BP from baseline through 48 h was more marked in the centhaquine group than in the control group. Compared with the control group, blood lactate level was lower by 1.75 ± 1.07 mmol/l in the centhaquine group on day 3 of resuscitation. Improvements in base deficit, multiple organ dysfunction syndrome (MODS) score and adult respiratory distress syndrome (ARDS) were greater in the centhaquine group than in the control group. CONCLUSION: When added to SOC, centhaquine is a well-tolerated and effective resuscitative agent. It improves the clinical outcome of patients with hypovolemic shock. TRIAL REGISTRATION: ClinicalTrials.gov identifier number: NCT04056065. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01760-4. standard of care (SOC) and was followed for 28 days. Results: Fifty patients were included, and 45 completed the trial: 22 in the control group and 23 in the centhaquine group. The demographics of patients in both groups were comparable. No adverse event related to centhaquine was recorded in the 28-day observation period. The baseline, Injury Scoring System score, haemoglobin, and haematocrit were similar in both groups. However, 91% of the patients in the centhaquine group needed major surgery, whereas only 68% in the control group (p = 0.0526). Twenty-eight-day all-cause mortality was 0/23 in the centhaquine group and 2/22 in the control group. The percent time in ICU and ventilator support was less in the centhaquine group than in the control group. The total amount of vasopressors needed in the first 48 h of resuscitation was lower in the centhaquine group than in the control group (3.12 ± 2.18 vs. 9.39 ± 4.28 mg). An increase in systolic and diastolic BP from baseline through 48 h was more marked in the centhaquine group than in the control group. Compared with the control group, blood lactate level was lower by 1.75 ± 1.07 mmol/l in the centhaquine group on day 3 of resuscitation. Improvements in base deficit, multiple organ dysfunction syndrome (MODS) score and adult respiratory distress syndrome (ARDS) were greater in the centhaquine group than in the control group. Conclusion: When added to SOC, centhaquine is a well-tolerated and effective resuscitative agent. It improves the clinical outcome of patients with hypovolemic shock. Trial Registration: ClinicalTrials.gov identifier number: NCT04056065. Keywords: Centhaquine; Haemorrhage; Hypovolemia; Resuscitative agent; Shock A multicentric, randomized, controlled trial was conducted to evaluate the safety and efficacy of centhaquine as an adjuvant to the standard of care in hypovolemic shock patients. Fifty patients were randomized 1:1 to receive centhaquine or saline. Centhaquine was administered at a dose of 0.01 mg/kg in 100 ml saline and infused over 1 h. The control group received 100 ml of saline over a 1-h infusion. Centhaquine was safe and well tolerated. There were no drug-related adverse events in the study. Centhaquine improved blood pressure, reduced blood lactate levels, and improved base deficit. The total amount of vasopressors needed was lower in the centhaquine group than in the control group. Multiple organ dysfunction syndrome (MODS) score and acute respiratory distress syndrome (ARDS) also improved with centhaquine. Hypovolemic shock is a life-threatening condition due to depletion of intravascular volume by extracellular fluid loss or blood loss [1] . Patients, if left untreated, can develop ischaemic injury of vital organs, leading to multi-organ failure [1] . About 61,000 in the US and 1.9 million people worldwide die because of haemorrhagic shock every year, and many patients die within the first 6 h [2, 3] . Immediate attention and management are needed to prevent multi-organ failure and death. Infusion of fluid offers the benefit of increasing the intravascular volume, but it rapidly moves out to the extravascular space. Damage control resuscitation prevents a formed clot from being dislodged, dilutes clotting factors, and accelerates haemorrhage because of elevated blood pressure [4] [5] [6] . Blood products in a balanced ratio of plasma, platelets, and red blood cells [7] are useful [8] ; however, if these measures are not adequate, vasopressors are added to resuscitate patients [9] . Common adverse effects of vasopressors include arrhythmias, fluid extravasation, and ischaemia [10, 11] . The current standard of care (SOC) is inadequate and resuscitative agents are decades old. Attempts to develop an effective resuscitative agent have not been successful. Agents that could decrease metabolic activity to reduce oxygen demand were studied [12] [13] [14] [15] , but none was promising. Haemoglobin-based blood substitutes were effective in animal models [16, 17] but failed in phase III clinical trials [18] [19] [20] and were dropped from further development. Centhaquine (Lyfaquin Ò ) has been found to be an effective resuscitative agent in rat, rabbit, and swine models of haemorrhagic shock [21] [22] [23] [24] [25] [26] [27] . Centhaquine significantly decreased blood lactate, increased mean arterial pressure, pulse pressure, cardiac output, and decreased mortality and increased animals' survival time with severe blood loss. Centhaquine appears to stimulate venous a2B adrenergic receptors to produce venous constriction and increase venous return to the heart, resulting in increased cardiac output and improved tissue perfusion. Centhaquine also acts on central a2A adrenergic receptors to reduce sympathetic drive and decrease arterial vascular resistance contributing to improved tissue blood perfusion [22] . Enhancing tissue blood perfusion is a significant advantage in reducing resuscitation volume and preventing extravasation of fluid and adverse effects of lung oedema. Centhaquine has no action on beta-adrenergic receptors, and therefore the risk of arrhythmias is mitigated. We performed a double-blind, randomized, and placebo-controlled phase I clinical study (CTRI/2014/06/004647; NCT02408731) [21, 22] to assess the safety and tolerability of centhaquine. Single ascending dose (SAD) and multiple ascending dose (MAD) study with centhaquine showed that it was well-tolerated and safe in healthy male volunteers [21] . None of the subjects experienced a serious adverse event in any cohort. We observed few non-serious adverse events (hypotension, high lactic acid, fall in respiratory rate, dryness of mouth, and drowsiness) at more than ten times higher than the therapeutic dose of 0.01 mg/kg. These events were transient and resolved without sequelae and any intervention. Based on these results, we conducted a phase II trial to evaluate the safety and efficacy of centhaquine in patients with hypovolemic shock due to blood loss. We conducted a multicentric, randomized, controlled, double-blind study primarily to determine the tolerability and safety of centhaquine given along with SOC in patients with hypovolemic shock due to blood loss with systolic blood pressure (SBP) B 90 mmHg. The secondary objective was to determine the efficacy of centhaquine as a resuscitative agent. Patients were assessed for eligibility based on the inclusion and exclusion criteria and randomized in a 1:1 ratio either to the centhaquine group receiving centhaquine (0.01 mg/kg) by IV infusion along with SOC or to the control group receiving SOC plus saline. According to the local hospital setting's treatment guidelines, the SOC generally included endotracheal intubation, administration of fluids, blood products, and vasopressors. The study duration for an individual patient was 28 days, including two study visits. Visit 1 on day 1 included screening, randomization, treatment, and visit 2 at the end of the study (day 28 ? 5). The patients randomized in this study were in a state of severe life-threatening shock. An Interactive Web Response System (IWRS) was used to randomize the eligible patient to the treatment groups. Each patient was monitored closely throughout his/her hospitalization and followed until discharge from randomization. Each patient was assessed for safety and efficacy parameters over 28 days from randomization. At baseline, we recorded various demographic data (age, gender, weight, height), chest x-ray, ECG, and vital signs. Blood tests at baseline included haematology, blood lactate, base deficit, lipid profile, kidney function tests, liver function tests, and serum electrolytes. We also noted the patient's physical examination, information about their medical history, concomitant illness, concomitant medications, and initial Glasgow coma scale (GCS) and ARDS scores. In this study, the patients were both males and females aged 18-70 years, with hypovolemic shock due to blood loss with SBP B 90 mmHg at presentation and continued receiving standard shock treatment, having body weight 45-85 kg. The female patients included were either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or if of childbearing potential, they agreed to use effective contraception through the study. Patients with postpartum haemorrhage were included. Exclusion criteria were patients with (1) a terminal illness (any other terminal illness developed during the 28-day observation period which was not associated with hypovolemic shock); (2) severe brain injury (GCS \ 8); (3) type of injury not known; (4) inability to obtain intravenous access; (5) known pregnancy; (6) cardiopulmonary resuscitation before randomization; (7) the presence of a do not resuscitate order; (8) taking beta-adrenergic antagonists; (9) untreated tension pneumothorax; (10) untreated cardiac tamponade; (11) bilateral absent pupillary light reflex (both pupils fixed and dilated); (12) participating in another interventional study; (13) systemic diseases which were present before having trauma, such as cancer, chronic renal failure, liver failure, decompensated heart failure, or AIDS. We took informed consent from every patient. For patients who were not fit to give consent at the time of initiation of treatment, their legally authorized representative (LAR) gave the consent, and we took re-consent of the patients as soon as their condition allowed. The investigator informed the patient/LAR in writing and audio-visual recording about all aspects of the study relevant to deciding whether to participate. The informed consent form included all the elements required by ICH-GCP recommendations and schedule Y. Centhaquine (Lyfaquin Ò ; lyophilized centhaquine citrate injection 1.0 mg) manufactured by Pharmazz India Private Limited at Gufic Biosciences Limited was provided to the investigators at the participating sites. Patients who met the eligibility criteria were randomized 1:1 to the centhaquine or control groups. Throughout the study, all patients in both groups received the best SOC for hypovolemic shock according to local institutional standard practice, including fluid resuscitation with crystalloids/colloids, blood products, and vasopressors. Centhaquine or placebo (normal saline) was administered intravenously after randomization to hypovolemic shock patients, an add-on to SOC, and all patients continued receiving standard treatment for hypovolemic shock. In the centhaquine group, intravenous infusion of centhaquine at a dose of 0.01 mg/kg body weight was carried out over 1 h in 100 ml normal saline. The next dose of centhaquine was administered if SBP fell or remained below or equal to 90 mmHg, but not before 4 h of the previous dose, and the total number of doses did not exceed three per day. Centhaquine administration, if needed, was continued for 2 days post-randomization. A minimum of one dose and a maximum of six doses of centhaquine were administered within the first 48 h post-randomization. Similar treatment was carried out in the control group using an equal volume of normal saline administered as an intravenous infusion over 1 h in 100 ml of normal saline post-randomization. Specific intravenous treatments and dose selection were based on preclinical and phase I safety and tolerability studies [21, 22] . An independent data safety monitoring board consisting of a clinician with experience in critical care medicine, a biostatistician, and a clinical pharmacologist monitored the trial's safety and efficacy. The data safety monitoring board reviewed each subject's safety data from the study and all serious adverse events, regardless of attribution, contemporaneously with submissions to the sponsor and investigator. Patients were randomized 1:1 to either centhaquine or placebo using block randomization. A statistician prepared the randomization list using a validated computer program, the statistical analysis system SPSS. An interactive web response system (IWRS) method containing randomization codes was used to randomize eligible patients to the treatment groups. The patients and all relevant personnel involved with the conduct and interpretation of the study (including the investigator, investigational site personnel, and the sponsor or designee's staff) were blinded to the identity of the assigned study drug (centhaquine/placebo) and the randomization codes. The biostatistician/unblinded pharmacist was independent of the study team. An unblinded monitor independent of the monitoring team monitored the dispensing activity. The final randomization list was kept strictly confidential and accessible only by authorized people per sponsor until completion of the study. Emergency unblinding through IWRS was available. All patients who received treatment were included in the safety analysis. Safety was assessed during treatment and the post-treatment follow-up period based on adverse events, physical examination, vital signs, ECG, and clinical laboratory parameters as per protocol. A complete set of haematological, biochemical, and organ function tests (complete blood count, blood glucose, lipid profile, serum electrolytes, liver function test, and kidney function test) was performed. Adverse events that occurred or worsened during treatment or posttreatment were recorded. All adverse events were coded by preferred term and system organ class using the latest version of the Medical Dictionary for Regulatory Activities. All patients were followed up for safety assessment at visit 1 (from day 1 to day 7 or discharge, whichever is earlier) and visit 2 (day 28 ? 5). The efficacy of centhaquine in patients of hypovolemic shock was assessed using (1) mortality through day 28 days; (2) days in ICU and on a ventilator; (3) total fluids and blood products requirement during first 48 h; (4) the total amount of vasopressor infused in first 48 h; (5) the number of doses of centhaquine administered in first 48 h post-randomization; (6) haemodynamic variables mean through 48 h; (7) blood haematocrit and haemoglobin mean through 48 h; (8) blood lactate and base deficit mean through day 3; (9) coagulation parameter mean through 28 days. Additionally, MODS, ARDS, and GCS means through 28 days were recorded. The data obtained from earlier clinical studies were considered for sample size determination for this phase II study. Trauma Center registry data suggest that 30-day mortality under the SOC protocol is between 16.4 and 29.2% [28] . A similar estimate of mortality (26%) was for the control group of the Resuscitation Outcomes Consortium pre-hospital hypertonic saline trial [29] . If we assume 18% mortality in the control group, a sample size of a minimum of 15 per group was required to achieve 80% power to detect a clinically significant (at 5% significant level) reduction in mortality of 66% (9.6% mortality) in the study group [30] . We further considered a 20% loss to follow-up, and with this, a total of 36 patients (18 in each group) was required. To increase the study's power, we increased the sample size to 50 patients (25 patients in each group). The results of the trial are presented as mean ± SEM. Unpaired t-test with Welch's correction was used to analyse data sets with unequal variances. The unpaired t-test was used to compare the discrete variables between the two data sets at baseline and follow-up. Nonparametric analysis was carried out using Kruskal-Wallis one-way ANOVA without assuming equal variances, and Tukey's multiple comparisons test estimated the significance of differences. A chi-square test was used to compare the groups. Baptista-Pike method was used to calculate the odds ratio. A P value \ 0.05 was considered significant at a 95% confidence level and 0.10 at a 90% confidence level. Demographic variables (age, weight, height, body surface area, and body mass index) and patient characteristics were summarized descriptively by treatment assignments. Continuous variables, such as patient age at enrolment, number of non-missing observations (n), mean, and SEM, were tabulated by treatment assignment. All available data were used in the analyses. Each group was summarized individually. Unavailable data were assessed as ''missing values'' and only the observed population was evaluated. The statistical analysis was processed with GraphPad Prism 8.1.1 (GraphPad, San Diego, CA, USA). The study was performed according to the Declaration of Helsinki principles, the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline for Good Clinical Practice (ICH-GCP), and local regulatory requirements. The study protocol (PMZ-02, version 2.0/dated 10 March 2016) was approved by the Drugs Controller General of India, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India (DCGI CT NOC. no.: CT/ ND/37/2016). Each institutional ethics committee also reviewed and approved the study protocol before initiating patient enrolment. The trial was registered at the Clinical Trials Registry, India (CTRI/2017/03/008184), and the United States National Library of Medicine, ClinicalTrials.gov (NCT04056065). Each site's ethics committee was informed of any protocol deviation, amendment, subject exclusion or withdrawal, and serious adverse events. A total of 137 patients were assessed in seven clinical sites across India, and 50 patients met the eligibility criteria. All patients received standard treatment for hypovolemic shock and were randomly assigned to either the control group (N = 26) who received standard treatment for shock and normal saline or the centhaquine group (N = 24) that received standard treatment for shock along with centhaquine. From the control group, 22 patients completed the study (2 patients withdrawn by the investigator, 2 patients withdrew the consent), and from the centhaquine group, 23 patients completed the study (1 patient withdrawn by the investigator) (Fig. 1 ). Demographics and baseline characteristics of patients were comparable between the two groups. More male than female patients were included in the control and centhaquine groups, and their proportion was similar in both groups (Table 1) . Age, body weight, height, BMI, and BSA were similar in each group (Table 1) . The Injury Scoring System (ISS) values of patients in the control and centhaquine groups were measured on day 1 (baseline). The ISS value indicates the severity of an injury which was a little higher in centhaquine group patients (23.14 ± 3.30) compared to controls (20.63 ± 2.45), although the difference did not reach the level of statistical significance. Baseline levels of haemoglobin (control 9.38 ± 0.71 g/dl vs. centhaquine 8.73 ± 0.55 g/dl) and haematocrit (control 28.79 ± 2.11% vs. centhaquine 26.71 ± 1.81%) were almost similar in control and centhaquine groups patients. The level of consciousness (GCS) of patients in both groups was similar (control 13.95 ± 0.44 vs. centhaquine 13.78 ± 0.45). Table 2 shows the case details of individual patients enrolled in each cohort. All patients received centhaquine or saline when they were in hypovolemic shock with SBP B 90 mmHg. The standard of care (SOC) for shock was provided to all the patients in both groups. SOC in both groups was practically similar (Table 3) . The vital signs of control and centhaquine groups are presented in Table 4 . There was an improvement in vital signs following resuscitation in both the control and centhaquine groups; however, improvement in systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure were more significant in the centhaquine group. Once recovered from hypovolemic shock, vital signs were similar in both groups of patients. The haematological parameters were similar in control and centhaquine groups at the time of inclusion in the study (day 1, baseline). The haematological parameters improved from day 1 (baseline) to day 28, and this improvement was similar in both groups. Centhaquine does not alter patients' haematological parameters in hypovolemic shock any differently from in the control group. (Table 5 ). The baseline (at the time the patient was included in the study) coagulation parameters (platelet count, prothrombin time, fibrinogen value, and international normalized ratio) in the control and centhaquine groups were similar. The improvement in coagulation parameters from day 1 (baseline) to day 3 and day 28 was similar in both groups. There was no significant Data are presented as mean ± standard error of the mean Open wound of (20 9 10 cm) over right lower leg and ankle. Right lower limb: Open comminuted fracture of right tibia and fibula bone exposed with bleeding. Soft tissue defect over anterior aspect of ankle. Anterior tendon and bone-exposed, abrasion wound over knee and thigh difference observed between the groups ( Table 5 ). The baseline lipid profile of the control and centhaquine groups was similar. The change in lipid profile from day 1 (baseline) to day 28 was similar in both groups. Centhaquine does not significantly affect the lipid profile of patients in hypovolemic shock (Table 5) . The baseline (day 1, time of patient inclusion) serum creatinine, blood urea nitrogen, and glomerular filtration rate of the control and centhaquine groups were similar. The improvement in kidney function parameters from day 1 (baseline) to day 28 was similar in both groups. No significant difference was observed between the groups ( Table 5 ). The baseline levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum bilirubin, alkaline phosphatase, and serum albumin of the control and centhaquine groups was similar. The improvement in liver function parameters from day 1 (baseline) to day 28 was similar in both groups (Table 5 ). Centhaquine does not affect patients' kidney and liver function markers in hypovolemic shock. The baseline serum electrolytes (sodium, potassium, and calcium) and blood glucose of control and centhaquine groups were similar. The improvement in electrolytes and blood glucose from day 1 (baseline) to day 28 was similar in both groups. There was no significant difference observed between the groups (Table 5) . Centhaquine does not affect serum electrolyte and blood glucose levels in hypovolemic shock patients. All patients who received treatment were included in the safety analysis. Two out of 22 patients died in the control group and none in the centhaquine group. Three adverse events were reported in three patients of the control group (N = 22). Of these three, two events were Data are presented as mean ± standard error of the mean serious (death), and one was moderate (viral hepatitis), which was resolved with medical intervention. Two moderate adverse events, diarrhoea in one and acute kidney injury (due to severe traumatic injury resulting in the amputation of a right lower limb combined with sepsis) in the other patient of the centhaquine group (N = 23), were reported, both resolved with medical intervention. None of the adverse events were related to the study drug. All-Cause Mortality Twenty-eight-day all-cause mortality was 9.1% in the control group, whereas it was 0% in the centhaquine group. Two out of 22 patients died within the first 48 h of resuscitation in the control group, while all 23 patients in the centhaquine group survived. Centhaquine group patients were in the hospital for a longer duration (14.87 ± 1.89 days) than control (10.75 ± 2.01 days). Major surgery was performed in 91.30% (21 out of 23) patients in the centhaquine group and 68.18% (15 out 22) in the control group (p = 0.0526). However, the ICU stay was only a little longer for centhaquine group patients (6.23 ± 1.31 days) than control group patients (5.26 ± 1.27 days). Percent stay in ICU was higher for control group patients (48.93%) compared to those taking centhaquine (41.89%). The difference between the means using a two-tailed, unpaired t-test with Welch's correction was -10.10 ± 10.16, 95% CI -30.63 to 10.44, p = 0.3262. Centhaquine group patients were on ventilator support for a shorter duration (0.89 ± 0.45 days) than control group patients who stayed on ventilator support for 1.96 ± 1.10 days ( Table 6 ). The difference between the means was -1.063 ± 1.186, 95% CI -3.493 to 1.367, p = 0.3778. When treated with centhaquine, patients with hypovolemic shock required a lesser (statistically insignificant) volume of fluids (4.26 ± 0.23 l) in the first 48 h compared to control (4.59 ± 0.41 l) group patients (twotailed, unpaired t-test, p = 0.4919). Patients with hypovolemic shock enrolled in the control and centhaquine groups required an almost similar amount of blood products in the first 48 h (control 0.88 ± 0.13 l and centhaquine 0.92 ± 0.15 l; two-tailed, unpaired t-test, p = 0.8933). Around 86.36% of patients in the control group and 86.96% of patients in the centhaquine group required blood products (Fig. 2) . Data are presented as mean ± standard error of the mean The total amount of vasopressors needed in the first 48 h of resuscitation was 9.39 ± 4.28 mg for patients in the control group, while only 3.12 ± 2.18 mg (p = 0.2013) in the centhaquine group (Fig. 2) Both the control and centhaquine groups of patients showed a significant increase in SBP in the first 48 h of randomization. The increase in SBP from baseline to 12, 24, and 48 h of resuscitation with centhaquine was highly significant (p \ 0.0001). In the control group of patients, the increase in SBP from baseline was comparatively less significant (Fig. 3) . At An increase in DBP at 12, 24, and 48 h from baseline occurred following resuscitation in both the control and centhaquine groups. An increase in DBP was more marked in the centhaquine group than in the controls (Fig. 4) (Fig. 4) . The mean difference between baseline and 48 h of resuscitation was Blood lactate levels (mmol/l) were 4.30 ± 0.96 and 4.34 ± 0.78 in the control and centhaquine groups, respectively, at baseline. It decreased to 3.19 ± 1.07 and 1.44 ± 0.13 in the control and centhaquine groups, respectively, at day 3. Centhaquine significantly (two-tailed, unpaired t-test with Welch's correction, the difference between the means was -2.902 ± 0.7865, 95% CI -4.529 to -1.276, p = 0.0012; 66.8%) decreased blood lactate levels with a high level of statistical significance. The decrease in blood lactate was not significant in control group patients (the difference between the means was -1.110 ± 1.437, 95% CI -4.013 to 1.792, p = 0.4441; 25.8%). (Fig. 5) . Analysis of change in lactate levels in individual patients using two-way ANOVA had a p-value of 0.0682 in the control and 0.0007 in the centhaquine group of (Fig. 5) . On comparison of blood lactate levels on day 3 between the control and centhaquine groups using a two-tailed, unpaired ttest with Welch's correction, the difference between the means was -1.752 ± 1.077, 95% CI -3.988 to 0.4839, p = 0.1183. Base deficit levels (mmol/l) improved from -7.40 ± 1.42 at baseline to -2.58 ± 1.49 at day 3 in the control group (difference between the means 4.823 ± 2.054, 95% CI 0.6768-8.969, p = 0.0237) and from -5.78 ± 1.22 at baseline to 1.33 ± 0.76 at day 3 in the centhaquine group (difference between the means 7.114 ± 1.439, 95% CI 4.913-10.03, p \ 0.0001). The baseline GCS score was similar in control and centhaquine group patients, and it improved through day 28 in both groups. On (1.17 ± 0.27) than controls (3.68 ± 1.45). The difference between the means of the control and centhaquine groups was 2.508 ± 1.486, 95% CI -0.5713 to 5.587, p = 0.1054). MODS improved through day 28 in both groups, but it was a little higher in the control group (0.26 ± 0.17) compared to centhaquine (0.17 ± 0.10). Centhaquine-treated patients had lower ARDS scores (0.08 ± 0.03) on day 2 than controls (0.57 ± 0.25). The difference between the means of the control and centhaquine groups was 0.4921 ± 0.2622, 95% CI -0.0519 to 1.036, p = 0.074). The ARDS score was higher in the control group during the 7-day hospitalization period. ARDS improved through day 28 in both groups (Table 7) . This multicentre trial provides evidence that centhaquine administration to hypovolemic shock patients had no evidence of adverse effects or complications and improved clinical outcome. The trial used the randomization method to ensure that participating clinicians did not know the treatment allocation and that the intervention did not influence the outcome assessment. The factors that could affect the prognosis were well balanced at the baseline, and all patients' follow-up was carried out randomly till the end of the study with minuscule potential for bias. Treatment of blood loss resulting in haemorrhagic shock has been guided by traditional practices rather than randomized clinical trials. In the past 10 years, a decrease in crystalloids and an increase in blood product use in ratios that depict blood transfusion have improved clinical outcome [6, 31] . Administering a sufficient fluid volume is essential during the early phases to stabilize haemodynamics, and fluid restriction may be helpful in later phases [32] . Fluids and vasopressors are still recognized as an essential part of resuscitation and are associated with undesired effects such as fluid responsiveness, extravasation of fluids, and cardiac complications [10, 11, 33] . There is a need to develop novel resuscitative agents that either Centhaquine is a resuscitative agent acting as an a-adrenergic receptor agonist. It acts on venous a2B adrenergic receptors to produce constriction and increase venous return to the heart, increasing cardiac output and tissue perfusion. It also acts on central a2A adrenergic receptors to reduce sympathetic drive and decrease systemic vascular resistance leading to improved tissue blood perfusion [22, 34] . The resuscitative effect of centhaquine is significantly blocked by a2 adrenergic receptor antagonists, yohimbine, or atipamezole [34] . Centhaquine does not act on beta-adrenergic receptors; therefore, the risk of cardiac arrhythmia is mitigated. There is a drop in cardiac pre-load in hypovolemic conditions to a critical level, resulting in a dramatic drop in cardiac output, leading to a decrease in tissue and organ perfusion, ultimately leading to multiple organ dysfunction and death. Patients' clinical outcome is predominantly monitored using biomarkers, blood pressure, and blood lactate levels. Vasopressors tend to increase blood pressure by causing arterial vasoconstriction and increasing heart rate. An increase in heart rate augments cardiac output. However, the force or rate of contraction cannot explain a significant cardiac output increase [35] . About two-thirds of blood volume is pooled in the venous system serving as an adjustable reservoir [36] . An increase in venous return from systemic veins into the right atrium significantly increases cardiac output by the Frank-Starling mechanism, resulting in increased arterial blood pressure and tissue perfusion. Based on the mechanism of action, centhaquine increases venous return to the heart and increases cardiac output and tissue perfusion, making it an ideal candidate for use as a resuscitative agent in treating patients with hypovolemic patients. The venous system is critical following haemorrhage in mobilizing unstressed blood volume to preserve or increase venous blood return to the heart and increase cardiac output [37, 38] . Centhaquine helps the venous system convert unstressed blood volume to stressed blood volume and optimize cardiac output to maintain blood circulation in a state of shock. The safety of centhaquine in hypovolemic shock patients was assessed based on adverse events, vital signs, and clinical laboratory parameters. Centhaquine did not show any clinically significant effect on vital signs, haematology, lipid profile, kidney functions, liver functions, and serum electrolytes (Table 4) . Patients with hypovolemic shock showed a fall in SBP, DBP, and pulse pressure. Centhaquine improved these vital parameters. Once patients recovered from hypovolemic shock, no clinically significant effect of centhaquine was observed on vital signs (Tables 4, 5). This study excluded patients with GCS \ 8 to avoid the added complication of damage to the CNS in patients with a severe head injury. Severe injury to the head can damage the brain and alter system haemodynamics and modify cardiovascular responses and influence the investigational drug outcome. Two out of 22 patients died in the control group and none in the centhaquine group. Three adverse events were reported in three patients of the control group (N = 22). Out of these three, two events were serious (death), and one was moderate (viral hepatitis), which was resolved with medical intervention. Two adverse events, diarrhoea in one and acute kidney injury (due to severe traumatic injury resulting in the amputation of a right lower limb combined with sepsis) in the other, were reported in the centhaquine group (N = 23); both were moderate in severity and resolved with medical intervention. All these adverse events in the control and centhaquine groups were not related to the study drug and were associated entirely with the patient's disease progression. Centhaquine was found to be safe and well tolerated in hypovolemic shock patients. Efficacy of centhaquine was assessed based on survival at 28 days; days in ICU; days on ventilator support; total fluids and blood product requirement during first 48 h; amount of total vasopressor infused in the first 48 h; haemodynamic variables; blood lactate; base deficit; MOD and ARDS scores. A significant correlation exists between blood loss and change in haemoglobin [39] , and a drop in haemoglobin reflects the blood loss [40] . Since the haemoglobin level was lower by 0.65 g/dl in the centhaquine group than in the controls, the blood loss was to some extent more in the centhaquine group at the time of enrolment. Two out of 22 patients died within the first 48 h of enrolment in the control group, while all 23 patients in the centhaquine group survived. The severity of injuries was significantly more in the centhaquine group, where 21 out of 23 (91.30%) patients needed major surgery following trauma, while only 15 out of 22 (68.18%) in the control group underwent surgery (p = 0.0526). However, centhaquine group patients stayed in the hospital for a longer duration than controls. However, the percent stay in ICU was higher for control group patients (48.93%) than for the centhaquine group (41.89%). The more extended hospital stays of centhaquine group patients were because of their health conditions, which were a little more severe than those of the control group patients as seen from their ISS score (control 20.63 ± 2.45 vs. centhaquine 23.14 ± 3.30), baseline haemoglobin (control 9.38 ± 0.71 g/dl vs. centhaquine 8.73 ± 0.55 g/dl) and haematocrit (control 28.79 ± 2.11% vs. centhaquine 26.71 ± 1.81%) levels. Centhaquine group patients were on ventilator support for a shorter duration (0.89 ± 0.45 days) than the control group patients who stayed on ventilator support for 1.96 ± 1.10 days. Although it did not reach the statistical significance level, the results indicate a better recovery of patients with centhaquine treatment (Table 6) . Centhaquine treated patients required a similar volume of fluids (4.26 ± 0.23 l) in the first 48 h of randomization compared to control (4.59 ± 0.41 L) group patients. Almost a similar volume of blood products was required by control and centhaquine group patients in the first 48 h of randomization. These data of fluids and blood products and other treatments shown in Table 4 indicate that patients from both groups received almost the same standard of care, avoiding biases. Most patients show improved blood pressure in response to the fluids shortly after their administration; however, this response is transient and is lost rapidly over time [41] . Using fluids is an attempt to improve tissue perfusion by improving cardiac output. Adding centhaquine to fluid administration augments cardiac output improvement through a different mechanism of action that complements each other. Vasopressors are used when patients in hypovolemic shock are poorly or not responding to fluids. Norepinephrine, phenylephrine, epinephrine, and dopamine are the commonly used vasopressors. These catecholamines enhance cardiac contractility and vascular tone and influence overall arterial, venous, and capillary pressures and blood flow. The dose of vasopressors needs to be carefully titrated and is associated with many adverse effects like arrhythmias, fluid extravasation, and ischaemia [10, 11] . Vasopressin is used both as adjunctive and first-line therapy, but studies have equivocal results [42] [43] [44] . Angiotensin II has recently been introduced for patients with vasodilatory shock [42, 45] . These vasopressors act on different receptors and through different pathways. Agents affecting the sympathetic system through a-and b-adrenergic receptors are available, but additional stimulation of these receptors is not apparent and could be helpful or even harmful [46] . The present study is critical, given that centhaquine acts through a2adrenergic receptors to increase cardiac output (via a2B) and decreased arterial resistance (via a2A) has shown promising efficacy in hypovolemic shock patients. A comparatively lesser amount of vasopressors was needed by the centhaquine group patients in the first 48 h of resuscitation than by the control group patients. Only 26.09% of patients from the centhaquine group required vasopressors, while 40.91% of patients from the control group needed them. Though the difference in mean values of total vasopressors between the groups was not statistically significant, the trend indicates a reduction in vasopressors' requirement in centhaquine treatment. Our findings are consistent with our preclinical studies conducted in an animal model of hypovolemic shock where rats treated with centhaquine required less norepinephrine to maintain their blood pressure [47] . A significant reduction in SBP and DBP occurs in hypovolemic shock, leading to a reduction in peripheral blood perfusion. Treatment with centhaquine showed a highly significant increase (p \ 0.0001) in SBP from baseline in the first 48 h of resuscitation, while in the control group, the increase in SBP was comparatively less significant than with centhaquine. A similar increase (p \ 0.0001) was seen in DBP in centhaquine treated patients, while in the control group of patients, minimal improvement in DBP occurred (Figs. 3, 4) . Changes in lactate levels provide an early and objective evaluation of a patient's response to therapy, and repeated lactate determinations have proved to be a reliable prognostic index for patients with haemorrhagic shock [48] . Early return of lactate levels to normal levels (\ 2.0 mmol/l) within 24 h is associated with improved mortality. A significant correlation was established between the admission base deficit and transfusion requirements within the first 24 h and the risk of post-traumatic organ failure or death [49] . In the present study, all the enrolled patients showed a significant increase in blood lactate and base deficit levels. Centhaquine treatment showed a significant reduction in blood lactate (p = 0.0012; 66.8%), while in the control group the reduction was not significant (0.441; 25.8%). Similarly, the centhaquine group showed a highly significant improvement in base deficit (p \ 0.0001), while in the control group, the reduction was less significant (p = 0.0237). Mortality in hypovolemic shock patients is mainly associated with multiple organ dysfunction because of hypoperfusion and severe acidosis. On day 3 of resuscitation, centhaquine-treated patients showed a lower MODS (1.17 ± 0.27) than controls (3.68 ± 1.45). Studies in a swine model of haemorrhagic shock showed that centhaquine significantly improved the Horowitz index (327 ± 10 and 392 ± 16 in the control and centhaquine group, respectively) and reduced pulmonary oedema [22, 25] . In the present study, centhaquine-treated patients showed comparatively lower ARDS scores than the control group patients with p = 0.074 indicating significance at 90% CI but not at 95% CI (Table 7) . In this phase II study, centhaquine was highly efficacious, with statistically significant improvements in blood lactate levels, base deficit, and blood pressure. An improvement in all the above clinical and biological markers appears to contribute towards improved outcomes and reduced deaths when centhaquine was added to the SOC. Results of this phase II study have confirmed previously observed efficacy in preclinical studies [21] [22] [23] [24] [25] [26] [27] . This study's limitation is that it was conducted in a small number of patients and was conducted in one country. Since this study involves a first-in-class drug product, we took this approach to have an appropriate comparison with a limited number of patients with similar baseline characteristics. Another limitation of the study was the assessment of tissue perfusion, including cardiac output, which was not done because of lack of accessibility. Information about a patient's cardiac functions is clinically desirable to manage hypovolemic shock better. However, this study's promising results have led to an efficacy study in a larger group of hypovolemic shock patients, investigating centhaquine in a multicentric, randomized, blinded, controlled efficacy clinical trial phase III (NCT04045327). In the future, other investigators and we may conduct further studies to test whether centhaquine and vasopressors complement each other in improving clinical outcomes of patients with hypovolemic shock. We would also like to investigate this hypothesis in septic shock patients. Another question is how chronic co-morbidities, such as hypertension and congestive heart failure, impact the efficacy of centhaquine. We recognize the demographics and SOC for the treatment of hypovolemic shock across the world may vary and that the efficacy of centhaquine needs to be established in populations across the world. Centhaquine (Lyfaquin Ò ) was safe and well tolerated in hypovolemic shock patients. This study is the first to assess the effect of centhaquine on clinical outcomes in patients in hypovolemic shock due to blood loss. Centhaquine is a highly effective resuscitative agent and appears to improve hypovolemic shock patients' clinical outcomes. Data Availability. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by-nc/4.0/. Calcium Gluconate 02-012 Inj Impact of trauma center volume on major vascular injury: an analysis of the National Trauma Data Bank (NTDB) Hemorrhagic shock Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study Prehospital intravenous fluid administration is associated with higher mortality in trauma patients: a National Trauma Data Bank analysis Reply to letter: ''Prehospital intravenous fluid administration is associated with higher mortality in trauma patients Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial Damage control resuscitation: directly addressing the early coagulopathy of trauma Fresh frozen plasma-to-packed red blood cell ratio and mortality in traumatic hemorrhage: nationwide analysis of 4,427 patients Vasopressors for hypotensive shock Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure Use of vasopressor increases the risk of mortality in traumatic hemorrhagic shock: a nationwide cohort study in Japan Valproic acid induces prosurvival transcriptomic changes in swine subjected to traumatic injury and hemorrhagic shock Effects of hydrogen sulfide on hemodynamics, inflammatory response and oxidative stress during resuscitated hemorrhagic shock in rats The mitochondria-targeted H2S-Donor AP39 in a murine model of combined hemorrhagic shock and blunt chest trauma Development and in vivo evaluation of a novel lyophilized formulation for the treatment of hemorrhagic shock Dose-dependent effect of diaspirin cross-linked hemoglobin on regional blood circulation of severely hemorrhaged rats Role of ET and NO in resuscitative effect of diaspirin crosslinked hemoglobin after hemorrhage in rat Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial Diaspirin crosslinked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX) Vascular endothelium and hypovolemic shock Centhaquine citrate. Alpha2B-Adrenoceptor ligand, resuscitative agent for hypovolemic shock Centhaquin improves resuscitative effect of hypertonic saline in hemorrhaged rats Efficacy of centhaquin as a small volume resuscitative agent in severely hemorrhaged rats Resuscitation with centhaquin and 6% hydroxyethyl starch 130/04 improves survival in a swine model of hemorrhagic shock: a randomized experimental study Resuscitative effect of centhaquin after hemorrhagic shock in rats Centhaquin improves survival in a swine model of hemorrhagic shock Prehospital use of plasma in traumatic hemorrhage (The PUPTH Trial): study protocol for a randomised controlled trial Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk Changing patterns of in-hospital deaths following implementation of damage control resuscitation practices in US forward military treatment facilities Aggressive fluid management in the critically ill: Pro Hypovolemic shock resuscitation Alpha adrenergic receptors mediate resuscitative effect of centhaquin in hemorrhaged rats Understanding venous return Bedside assessment of mean systemic filling pressure Measurement of mean systemic filling pressure after severe hemorrhagic shock in swine anesthetized with propofol-based total intravenous anesthesia: implications for vasopressor-free resuscitation Venous return and clinical hemodynamics: how the body works during acute hemorrhage Relationship between haemoglobin change and estimated blood loss after delivery Hemoglobin drop following postpartum hemorrhage Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDRO-MEDA-SHOCK randomized clinical trial Broad spectrum vasopressors: a new approach to the initial management of septic shock? Crit Care Early and sustained vasopressin infusion augments the hemodynamic efficacy of restrictive fluid resuscitation and improves survival in a liver laceration model of hemorrhagic shock Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial Angiotensin II for the treatment of vasodilatory shock Research Committee of the Surviving Sepsis C, Members of the Surviving Sepsis Campaign Research Committee contributing to this article are as f, Co-chair AGA, et al. The surviving sepsis campaign: fluid resuscitation and vasopressor therapy research priorities in adult patients Centhaquin decreases the requirement of norepinephrine, maintains blood pressure and improves survival following resuscitation of hemorrhaged rats Lactate clearance as a predictor of mortality in trauma patients Targeted resuscitation improves coagulation and outcome We thank all the study participants, patients, and their families.Funding. Pharmazz, Inc., Willowbrook, IL, USA, provided funding for this study and paid the journal's Rapid Service and Open Access fee.Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.